Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)

Market Cap	64.71B -18.5%
Revenue (ttm)	49.99B +6.2%
Net Income	4.11B +4.4%
EPS	1.51 +5.2%
Shares Out	n/a
PE Ratio	10.86
Forward PE	18.38
Dividend	0.45 (2.75%)
Ex-Dividend Date	Jul 16, 2026

Volume	300,733
Open	16.44
Previous Close	16.43
Day's Range	16.30 - 16.48
52-Week Range	14.90 - 24.42
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About HKG:2196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, car...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 40,684
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2196

Financial Performance

In 2025, HKG:2196's revenue was 41.66 billion, an increase of 1.45% compared to the previous year's 41.07 billion. Earnings were 3.37 billion, an increase of 21.69%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error